Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) - Pipeline Review, H1 2018

Publisher Name :
Date: 12-Jun-2018
No. of pages: 67

Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) - Pipeline Review, H1 2018

Summary

Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) - Proto-oncogene tyrosine-protein kinase ROS is an enzyme that in humans is encoded by the ROS1 gene. It activates several downstream signaling pathways related to cell differentiation, proliferation, growth and survival including the PI3 kinase-mTOR signaling pathway. It mediates the phosphorylation of PTPN11, an activator of this pathway. It phosphorylate and activate the transcription factor STAT3 to control anchorage-independent cell growth. It mediates the phosphorylation and the activation of VAV3, a guanine nucleotide exchange factor regulating cell morphology.

Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) pipeline Target constitutes close to 6 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II and Phase I stages are 1, 1, 2 and 1 respectively.

Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology which include indications Non-Small Cell Lung Cancer, Anaplastic Large Cell Lymphoma (ALCL), Neuroblastoma, Solid Tumor, Bile Duct Cancer (Cholangiocarcinoma), Colorectal Cancer, Glioblastoma Multiforme (GBM), Metastatic Colorectal Cancer, Neuroendocrine Tumors, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Anaplastic Thyroid Cancer, Brain Cancer, Breast Cancer, Central Nervous System (CNS) Tumor, Clear Cell Squamous Cell Carcinoma, Fibrosarcoma, Gastric Cancer, Head And Neck Cancer, Metastatic Breast Cancer, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Melanoma, Metastatic Ovarian Cancer, Metastatic Transitional (Urothelial) Tract Cancer, Non-Hodgkin Lymphoma, Non-Small Cell Lung Carcinoma, Ovarian Cancer, Pancreatic Cancer, Papillary Renal Cell Carcinoma, Papillary Thyroid Cancer, Prostate Cancer, Renal Cell Carcinoma, Rhabdomyosarcoma, Salivary Gland Cancer and Uveal Melanoma.

The latest report Proto Oncogene Tyrosine Protein Kinase ROS - Pipeline Review, H1 2018, outlays comprehensive information on the Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1)

- The report reviews Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects

- The report assesses Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) - Pipeline Review, H1 2018

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) - Overview
Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) - Companies Involved in Therapeutics Development
Daiichi Sankyo Co Ltd
Ignyta Inc
Pfizer Inc
Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) - Drug Profiles
crizotinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DS-6051 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
entrectinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lorlatinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TPX-0005 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
WY-135 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) - Dormant Products
Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) - Product Development Milestones
Featured News & Press Releases
Jun 02, 2018: Updated Phase 1 results of crizotinib against MET-amplified non-small cell lung cancer
May 29, 2018: Pfizer's XALKORI (crizotinib) Receives FDA Breakthrough Therapy Designation in Two New Indications
May 14, 2018: TP Therapeutics Appoints Athena Countouriotis, M.D., as EVP and Chief Medical Officer
Apr 15, 2018: Crizotinib Yielded a High Objective Response Rate for Adult Patients With ALK-positive Inflammatory Myofibroblastic Tumor
Apr 02, 2018: Lung cancer drug shows promise as targeted therapy for thousands with breast cancer
Feb 27, 2018: TP Therapeutics Appoints Lewis Shuster to Board of Directors
Feb 12, 2018: U.S., EU and Japan Health Authorities Accept Regulatory Submissions for Review of Pfizer's Third-Generation ALK Inhibitor Lorlatinib
Feb 05, 2018: Adding crizotinib to radiation therapy may help preserve hearing in patients with NF2
Dec 08, 2017: Largest trial ever performed in alveolar soft part sarcoma: results published
Dec 04, 2017: TP Therapeutics Appoints Sheila K. Gujrathi, MD to Board of Directors and as a Strategic Advisor
Nov 14, 2017: XALKORI Approved by Health Canada for the Treatment of Patients with ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Oct 17, 2017: Ignyta Receives European Medicines Agency Prime Designation for Entrectinib in NTRK Fusion-Positive Solid Tumors
Oct 17, 2017: Interim Analysis of Ignytas Entrectinib Suggests Potential Best-in-Class Profile as a First-Line Targeted Therapy in Patients with ROS1-Positive Non-Small Cell Lung Cancer
Oct 17, 2017: Promising Phase 1/2 Results for Entrectinib Against ROS1+ Non-Small Cell Lung Cancer
Oct 16, 2017: Pfizer Presents Full Results From Phase 2 Study of Next-generation Investigational ALK-inhibitor Lorlatinib in ALK-positive and ROS1-positive Advanced Non-small Cell Lung Cancer
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indications, H1 2018
Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Products under Development by Companies, H1 2018 (Contd..2), H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Daiichi Sankyo Co Ltd, H1 2018
Pipeline by Ignyta Inc, H1 2018
Pipeline by Pfizer Inc, H1 2018
Dormant Projects, H1 2018

List of Figures
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
  • Global Vegetable Capsules Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 22-Jun-2018        Price: US 3480 Onwards        Pages: 129
    Vegetarian capsules are all-natural, GMO free, plant-based shell, free from animal derivatives, gluten, and modified sugars. Nowadays, Vegetarian capsules can be divided into several kinds such as Plant Polysaccharides (Pullulan), Starches, and HPMC (Hydroxyl Propyl Methyl Celluloses). Vegetarian capsules possess the benefits of suited for Halal or Kosher certification; Pure, clear and elegant appearance with no taste or odor; Ideal for improving the bioavailability of oil soluble ingredients; E......
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Vegetable Capsules Market 2018, Forecast to 2023
    Published: 22-Jun-2018        Price: US 4880 Onwards        Pages: 131
    Vegetarian capsules are all-natural, GMO free, plant-based shell, free from animal derivatives, gluten, and modified sugars. Nowadays, Vegetarian capsules can be divided into several kinds such as Plant Polysaccharides (Pullulan), Starches, and HPMC (Hydroxyl Propyl Methyl Celluloses). Vegetarian capsules possess the benefits of suited for Halal or Kosher certification; Pure, clear and elegant appearance with no taste or odor; Ideal for improving the bioavailability of oil soluble ingredients; E......
  • Global Sugar Sphere Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 22-Jun-2018        Price: US 3480 Onwards        Pages: 131
    Sugar spheres are a widely used excipient for sustained-release pellet formulations. Sugar spheres (also called neutral pellets, nonpareil seeds, microgranules or sugar beads) are produced, preferably using a layered sugar-coating structure. The result is sugar spheres with sufficient mechanical stability for further processing. Scope of the Report: This report focuses on the Sugar Sphere in global market, especially in North America, Europe and Asia-Pacific, South America,......
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Sugar Sphere Market 2018, Forecast to 2023
    Published: 22-Jun-2018        Price: US 4880 Onwards        Pages: 132
    Sugar spheres are a widely used excipient for sustained-release pellet formulations. Sugar spheres (also called neutral pellets, nonpareil seeds, microgranules or sugar beads) are produced, preferably using a layered sugar-coating structure. The result is sugar spheres with sufficient mechanical stability for further processing. Scope of the Report: This report focuses on the Sugar Sphere in global market, especially in North America, Europe and Asia-Pacific, South America,......
  • Global Androstenedione Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 21-Jun-2018        Price: US 3480 Onwards        Pages: 152
    Androstenedione: 4-Androstenedione (androst-4-ene-3,17-dione) - an endogenous weak androgen and estrogen and intermediate to/prohormone of testosterone. Scope of the Report: This report focuses on the Androstenedione in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application. Androstenedione is used to evaluate the function of t......
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Androstenedione Market 2018, Forecast to 2023
    Published: 21-Jun-2018        Price: US 4880 Onwards        Pages: 148
    Androstenedione: 4-Androstenedione (androst-4-ene-3,17-dione) - an endogenous weak androgen and estrogen and intermediate to/prohormone of testosterone. Scope of the Report: This report focuses on the Androstenedione in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application. Androstenedione is used to evaluate the function of t......
  • Global Soft Gelatin Capsules Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 21-Jun-2018        Price: US 3480 Onwards        Pages: 152
    Soft Gelatin Capsules are a type of capsules with a solid outer shell and inner surrounding a liquid or semi-solid (inner fill) active ingredient that can be incorporated into the outer shell, the inner fill, or both. Scope of the Report: This report focuses on the Soft Gelatin Capsules in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and ap......
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Soft Gelatin Capsules Market 2018, Forecast to 2023
    Published: 21-Jun-2018        Price: US 4880 Onwards        Pages: 150
    Soft Gelatin Capsules are a type of capsules with a solid outer shell and inner surrounding a liquid or semi-solid (inner fill) active ingredient that can be incorporated into the outer shell, the inner fill, or both. Scope of the Report: This report focuses on the Soft Gelatin Capsules in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and ap......
  • Global Keyhole Limpet Hemocyanin (KLH) Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 20-Jun-2018        Price: US 3480 Onwards        Pages: 129
    KLH, which can be used as an active pharmaceutical ingredient ("API"), is a very large, high molecular weight, oxygen-carrying glycoprotein made of millions of atoms. There are two KLH subunit forms, KLH1 and KLH2, each composed of seven or eight functional units, with each functional unit having an oxygen binding site of two copper atoms. Keyhole limpet hemocyanin is an extremely large, heterogeneous glycosylated protein consisting of subunits with a molecular weight of 350,000 and 390,000 in a......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs